Former Commerce Official Lynn Fischer Fox Featured in STAT and Law360 on Pharma Tariffs

Lynn Fischer Fox, International Trade partner and former Deputy Assistant Secretary with the U.S. Department of Commerce, spoke with STAT and Law360 about pharmaceutical industry concerns over proposed import tariffs.

In the STAT article, "How to think about Trump's pharma tariffs — before they hit," Fischer Fox highlighted the complexity of pharmaceutical products, noting that medicines often rely on different components or production activities by country. She cautioned that a one-size-fits-all approach could lead to shortages and price spikes.

In the Law360 story, "Big Pharma Touts US Investments Amid Tariff Threat," Fischer Fox noted that pharma has traditionally been spared from tariffs, but current indications suggest that officials are "planning to move in a very expedited fashion to wrap up the investigation and move toward imposing tariffs." She highlighted that the sector has "such a wide variety of supply chains and sizes of companies that a single approach is very likely to be incredibly disruptive or very damaging to some sectors."

Read the STAT article (subscription required)

Read the Law360 article (subscription required).